RxDoctor Payments Data

Darshankumar Dave, MD

Neurology · Charleston, WVNPI 1033155437

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.4% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 42.1% of the total.

$2,514in general payments, 2019–2025

Across 104 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$420
  • Pfizer$313
  • Amgen$210
  • Teva Pharmaceuticals USA, Inc.$193
  • Lilly USA, LLC$118
  • plus $201 from 6 others

What the payments were for

  • Food & beverage$2,29891%
  • Education$2169%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,514 in reported general payments places this provider in the 65th percentile of 93 neurology providers in West Virginia.

See all neurology providers in West Virginia

Medicare billing

Part B allowed, 2024
$681,142
Medicare patients
1,290
Services billed
6,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$172,514
PanzygaImmun Glob G(Igg)-Ifas/Glycine12$91,037
Aimovig AutoinjectorErenumab-Aooe42$33,845
Nurtec OdtRimegepant Sulfate21$25,995
ValtocoDiazepam12$14,326
Lacosamide48$6,174
Clobazam19$3,431
Levetiracetam112$2,903
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$2,614
Gabapentin157$2,107
Primidone76$2,082
Zonisamide56$1,833
Oxcarbazepine29$1,380
Carbidopa-LevodopaCarbidopa/Levodopa67$978
Sumatriptan Succinate28$808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$313$117,03333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 93 neurology providers in West Virginia.

Other neurology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →